JP2024515629A5 - - Google Patents

Info

Publication number
JP2024515629A5
JP2024515629A5 JP2023562895A JP2023562895A JP2024515629A5 JP 2024515629 A5 JP2024515629 A5 JP 2024515629A5 JP 2023562895 A JP2023562895 A JP 2023562895A JP 2023562895 A JP2023562895 A JP 2023562895A JP 2024515629 A5 JP2024515629 A5 JP 2024515629A5
Authority
JP
Japan
Prior art keywords
seq
composition
composition according
transgene
tumor suppressor
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
JP2023562895A
Other languages
English (en)
Japanese (ja)
Other versions
JP2024515629A (ja
Filing date
Publication date
Application filed filed Critical
Priority claimed from PCT/US2022/024680 external-priority patent/WO2022221447A1/en
Publication of JP2024515629A publication Critical patent/JP2024515629A/ja
Publication of JP2024515629A5 publication Critical patent/JP2024515629A5/ja
Pending legal-status Critical Current

Links

JP2023562895A 2021-04-14 2022-04-13 ニューロフィブロミン２／マーリン（ｎｆ２）遺伝子療法のための材料及び方法 Pending JP2024515629A (ja)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202163174803P 2021-04-14 2021-04-14
US63/174,803 2021-04-14
PCT/US2022/024680 WO2022221447A1 (en) 2021-04-14 2022-04-13 Materials and methods for neurofibromin 2/merlin (nf2) gene therapy

Publications (2)

Publication Number Publication Date
JP2024515629A JP2024515629A (ja) 2024-04-10
JP2024515629A5 true JP2024515629A5 (cg-RX-API-DMAC7.html) 2025-04-22

Family

ID=83639721

Family Applications (1)

Application Number Title Priority Date Filing Date
JP2023562895A Pending JP2024515629A (ja) 2021-04-14 2022-04-13 ニューロフィブロミン２／マーリン（ｎｆ２）遺伝子療法のための材料及び方法

Country Status (6)

Country Link
US (1) US20240189453A1 (cg-RX-API-DMAC7.html)
EP (1) EP4323014A4 (cg-RX-API-DMAC7.html)
JP (1) JP2024515629A (cg-RX-API-DMAC7.html)
AU (1) AU2022257000A1 (cg-RX-API-DMAC7.html)
CA (1) CA3216712A1 (cg-RX-API-DMAC7.html)
WO (1) WO2022221447A1 (cg-RX-API-DMAC7.html)

Family Cites Families (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5707863A (en) * 1993-02-25 1998-01-13 General Hospital Corporation Tumor suppressor gene merlin
US5578462A (en) * 1994-01-10 1996-11-26 Bristol-Myers Squibb Company NF2 isoforms
RU2432158C1 (ru) * 2010-07-28 2011-10-27 Закрытое акционерное общество "Институт прикладной нанотехнологии" Профилактический бактерицидный лак для обработки ногтей
US20130137753A1 (en) * 2010-08-03 2013-05-30 University Of South Alabama Methods and compositions for the diagnosis and treatment of breast cancer
WO2015171270A1 (en) * 2014-05-06 2015-11-12 Felder Mitchell S Method for the treatment of neurofibromatosis
SG10201913266UA (en) * 2015-12-11 2020-02-27 Massachusetts Eye & Ear Infirmary Materials and methods for delivering nucleic acids to cochlear and vestibular cells
JP2024520815A (ja) * 2021-06-08 2024-05-24 エヌエフ２ セラピューティクス， インコーポレイテッド 神経線維腫性障害を処置するための組成物および方法

Similar Documents

Publication Publication Date Title
JP2022508182A5 (cg-RX-API-DMAC7.html)
AU2026202070A1 (en) Modified AAV capsid polypeptides for treatment of muscular diseases
Tal Adeno-associated virus-based vectors in gene therapy
IL278213B1 (en) A gene therapy vector encoding an e3 ubiquitin protein ligase (park2) and use thereof in treating or inhibiting the onset of parkinson’s disease (pd)
JP2020533959A5 (cg-RX-API-DMAC7.html)
RU2014137450A (ru) Композиции вектора aav и способы переноса генов в клетки, органы и ткани
US12359219B2 (en) Transgene cassettes designed to express a human MECP2 gene
JP2024099770A5 (cg-RX-API-DMAC7.html)
JP2020054367A (ja) 改変ｇ６ｐｃをコードするアデノ随伴ウイルスベクターおよびその使用
JP2022525302A5 (cg-RX-API-DMAC7.html)
JP2023515072A5 (cg-RX-API-DMAC7.html)
JP2022524434A5 (cg-RX-API-DMAC7.html)
JP2017529395A5 (cg-RX-API-DMAC7.html)
JP2020519629A5 (cg-RX-API-DMAC7.html)
JP2021508241A5 (cg-RX-API-DMAC7.html)
US20240269161A1 (en) Methods and compositions for tau reduction gene therapy
JP2023537358A5 (cg-RX-API-DMAC7.html)
CN120380153A (zh) 用于中枢神经系统中的基因表达的核酸调控元件以及使用方法
JP2023059858A5 (cg-RX-API-DMAC7.html)
JP2021520811A5 (cg-RX-API-DMAC7.html)
CN114144518A (zh) 用于基因疗法的双亮氨酸拉链激酶抑制剂
WO2021211700A1 (en) Compositions and methods for treatment of neurological disorders
JP2024543253A5 (cg-RX-API-DMAC7.html)
JP7641911B2 (ja) 新型の酵素組成物
JP2024515629A5 (cg-RX-API-DMAC7.html)